A series of Ecological Construction Programs have been initiated to protect the condition of grasslands in China during recent decades. However, grassland degradation is still severe, and conditions have not been restored as intended. This paper aims to empirically examine the effectiveness of these programs for protecting the grassland condition in the extensive pastoral areas of China. We focus on one major program that has been implemented widely on the grasslands, the Subsidy and Incentive System for Grassland Conservation (SISGC). The normalized difference vegetation index, measured with remote sensing technology, is used to quantify the grassland condition between 2001 and 2014. With data from 54 counties in the pastoral areas of Inner Mongolia, we estimate the impact of SISGC on the grassland condition. A fixed effects model is employed to control for livestock production, climate, time trends, and time‐invariant heterogeneity between counties. The model results provide quantitative evidence that the condition of the grasslands has improved significantly because of SISGC; but that the effectiveness of SISGC was offset to some extent by other socio‐economic and climate factors, such as increased producer prices and high temperature. This may explain why the actual grassland degradation has not been prevented as effectively as was expected. In addition, the impact of SISGC was stronger in counties with worse initial grassland condition. Furthermore, the effects of producer prices and climate changes were also more pronounced in these counties. Copyright © 2017 John Wiley & Sons, Ltd.

No abstract

ObjectivesThis work aims to explore whether HOX transcript antisense intergenic RNA (HOTAIR) polymorphisms are associated with cancer susceptibility.Materials and methodsA comprehensive search was conducted for literature published from January 2007 to July 2017. The pooled odds ratios (ORs) and the corresponding 95% CIs were calculated using the Revman 5.2 software. Eighteen articles of 36 case–control studies were enrolled including six HOTAIR polymorphisms and 10 cancer types.ResultsThe results showed that cancer risk was elevated in recessive mutation of rs12826786 (TT vs CC+CT: OR =1.55, 95% CI =1.19, 2.03; TT+CT vs CC: OR =1.23, 95% CI =1.04, 1.46; TT vs CC: OR =1.67, 95% CI =1.24, 2.24; T vs C: OR =1.24, 95% CI =1.09, 1.40) and rs920778 (TT vs CC+CT: OR =1.73, 95% CI =1.30, 2.30; TT+CT vs CC: OR =1.40, 95% CI =1.16, 1.70; TT vs CC: OR =1.83, 95% CI =1.25, 2.68; T vs C: OR =1.37, 95% CI =1.18, 1.59), while the results for polymorphisms of rs7958904, rs4759314, rs874945, and rs1899663 were insignificant. The stratified results for Chinese population were consistent with the overall group analysis.ConclusionOur meta-analysis showed that HOTAIR polymorphisms of rs12826786 and rs920778 were correlated with increased cancer risk, while rs7958904, rs4759314, rs874945, and rs1899663 were not. More studies with different types of cancer are needed to confirm the findings.

No abstract

The standard radiation dose 50.4 Gy with concurrent chemotherapy for localized inoperable esophageal cancer as supported by INT-0123 trail is now being challenged since a radiation dose above 50 Gy has been successfully administered with an observable dose–response relationship and insignificant untoward effects. Therefore, to ascertain the treatment benefits of different radiation doses, we performed a meta-analysis with 18 relative publications. According to our findings, a dose between 50 and 70 Gy appears optimal and patients who received ≥ 60 Gy radiation had a significantly better prognosis (pooled HR = 0.78, P = 0.004) as compared with < 60 Gy, especially in Asian countries (pooled HR = 0.75, P = 0.003). However, contradictory results of treatment benefit for ≥ 60 Gy were observed in two studies from Western countries, and the pooled treatment benefit of ≥ 60 Gy radiation was inconclusive (pooled HR = 0.86, P = 0.64). There was a marginal benefit in locoregional control in those treated with high dose (> 50.4/51 Gy) radiation when compared with those treated with low dose (≤ 50.4/51 Gy) radiation (pooled OR = 0.71, P = 0.06). Patients that received ≥ 60 Gy radiation had better locoregional control (OR = 0.29, P = 0.001), and for distant metastasis control, neither the > 50.4 Gy nor the ≥ 60 Gy treated group had any treatment benefit as compared to the groups that received ≤ 50.4 Gy and < 60 Gy group respectively. Taken together, a dose range of 50 to 70 Gy radiation with CCRT is recommended for non-operable EC patients. A dose of ≥ 60 Gy appears to be better in improving overall survival and locoregional control, especially in Asian countries, while the benefit of ≥ 60 Gy radiation in Western countries still remains controversial.